Development and Scale-Up of a Key Copper-Catalyzed Biaryl Ether Formation for the Multikilogram Synthesis of Emprumapimod

Emprumapimod was a p38α MAPK inhibitor developed for LMNA-related dilated cardiomyopathy. One key modification from the discovery synthesis to the manufacturing synthesis involved moving the biaryl ether formation toward the end of the synthetic sequence. Herein, we discuss the redesigned route to s...

Full description

Saved in:
Bibliographic Details
Published in:Organic process research & development 2024-04, Vol.28 (4), p.1253-1259
Main Authors: Brearley, Christopher, Bright, Robert David, Clarke, James, Critcher, Douglas J., Torres, Susana, Edwards, Ingrid, Fenton, Harriet, Huang, Shanjun, Johnson, Rebecca Amy, Jones, Ricky A., Mathew, Suju P., Norster, Rhys, Starbuck, Kathryn Alice, Taylor-Young, Amelia, Waddington, William, Walton, Robert, Wang, Jimmy
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Emprumapimod was a p38α MAPK inhibitor developed for LMNA-related dilated cardiomyopathy. One key modification from the discovery synthesis to the manufacturing synthesis involved moving the biaryl ether formation toward the end of the synthetic sequence. Herein, we discuss the redesigned route to suit large-scale manufacture. The development of a copper-catalyzed biaryl etherification reaction is detailed, including high-throughput experiments, process development and optimization, and purification. Subsequent amide formation afforded desired emprumapimod, delivering 82 kg of API across three batches. We anticipate this report will further support the utilization of nonprecious metal catalysis in pharmaceutical manufacture processes.
ISSN:1083-6160
1520-586X
DOI:10.1021/acs.oprd.4c00052